Skip to content

Advertisement

  • Oral presentation
  • Open Access

Cytokines, chemokines and leukotrienes profile and signature analysis in HTLV-1 infection as an evidence of disease progression

  • 1,
  • 1Email author,
  • 2,
  • 2,
  • 1,
  • 1,
  • 1,
  • 3,
  • 4,
  • 2,
  • 2,
  • 1,
  • 3 and
  • 5
Retrovirology201411 (Suppl 1) :O37

https://doi.org/10.1186/1742-4690-11-S1-O37

  • Published:

Keywords

  • Infectious Disease
  • Negative Correlation
  • Serum Sample
  • Signature Analysis
  • Prognostic Marker

Background

A cross-sectional study evaluated the cytokines, chemokines and leukotrienes profiles as possible biomarkers of progression to HTLV-1 associated myelopathy (HAM).

Methods

Serum samples from 21 healthy blood donors (HBD), 27 asymptomatic carriers (ASC), 32 possible HAM (pHAM) and 28 HAM individuals were tested for cytokines (IL-6, IFN-γ, TNF-α, IL-2, IL-4 and IL-10), chemokines ( RANTES, MCP1, IL-8, MIG and IP-10) and leukotrienes (CysLTs and LTB-4). For each molecule tested, the HTLV-1 individuals were classified as low or high-producers taking the global median index of the HBD group as a cut off.

Results

When comparing AS and pHAM individuals, AS were high-producers of IP-10 and low-producers of RANTES; pHAM were high-producers of IL-2 and low of IL-8. Besides, AS individuals presented a strong positive correlation between the regulatory cytokines IL-10 with IL-4 and between both with the pro-inflammatory cytokines IL-2 and IL-6; a negative correlation was found between RANTES and IL-2. HAM were high-producers of IL-6, IFN-γ, IP-10, LTB4, IL-4, MIG, IL-10, IL-2, presented a positive correlation of TNF-α and IFN-γ with IL-6, but this group had a positive correlation of CysLT with IL-10, IL-4 and TNF-α, contrasting with other groups.

Discussion

HAM displayed a unique signature of inflammation, which was strengthened by CysLT and not counterbalanced by IL-4 and IL-10. This signature was observed in pHAM to a lower extent, becoming more evident in HAM. This profile may indicate disease progression and may serve as prognostic markers in future studies.

Authors’ Affiliations

(1)
Curso de Pós-Graduação em Infectologia e Medicina Tropical, Faculdade de Medicina da Universidade Federal de Minas Gerais - Belo Horizonte, Minas Gerais, Brazil
(2)
Laboratório de Biomarcadores de Diagnóstico e Monitoração, Centro de Pesquisa René Rachou, FIOCRUZ-Minas, Belo Horizonte, Minas Gerais, Brazil
(3)
Fundação Centro de Hematologia e Hemoterapia de Minas Gerais, HEMOMINAS, Minas Gerais, Brazil
(4)
Hospital Sarah Kubitschek, Belo Horizonte, Minas Gerais, Brazil
(5)
Faculdade de Farmácia da USP, Ribeirão Preto, São Paulo, Brazil

Copyright

Advertisement